arsenic trioxide-aft arsenic trioxide 12 mg/12 ml concentrated solution for injection vial
aft pharmaceuticals pty ltd - arsenic trioxide, quantity: 12 mg - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - for the induction of remission and consolidation in patients with acute promyelocytic leukaemia (apl) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose apl is characterised by the presence of the t(15:17) translocation or pml/rar-alpha gene expression.,for the induction of remission and consolidation in patients with previously untreated acute promyelocytic leukaemia (apl) in combination with all-trans retinoic acid (atra) and/or chemotherapy and whose apl is characterised by the presence of the t(15:17) translocation or pml/rar-alpha gene expression.
arsenic trioxide for injection solution
sandoz canada incorporated - arsenic trioxide - solution - 10mg - arsenic trioxide 10mg - antineoplastic agents
phenasen arsenic trioxide 10 mg/10 ml injection vial
phebra pty ltd - arsenic trioxide, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - for the induction of remission and consolidation in patients with acute promyelocytic leukaemia (apl) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose apl is characterised by the presence of the t(15:17) translocation or pml/rar-alpha gene expression. for the induction of remission and consolidation in patients with previously untreated acute promyelocytic leukaemia (apl), in combination with all-trans retinoic acid (atra) and/or chemotherapy and whose apl is characterised by the presence of the t(15:17) translocation or pml/rar-alpha gene expression.
trisenox
medison pharma ltd - arsenic trioxide - solution for injection - arsenic trioxide 1 mg/ml - arsenic trioxide - arsenic trioxide - trisenox is indicated for induction of remission, and consolidation in adult patients with:• newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (apl) (white blood cell count, ≤ 10 x 1000/μl) in combination with all-trans-retinoic acid (atra)• relapsed/refractory acute promyelocytic leukaemia (apl)(previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor-alpha (pml/rar-alpha) gene.the response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.
teva-arsenic trioxide for injection solution
teva canada limited - arsenic trioxide - solution - 10mg - arsenic trioxide 10mg - antineoplastic agents
teva-arsenic trioxide for injection solution
teva canada limited - arsenic trioxide - solution - 12mg - arsenic trioxide 12mg - antineoplastic agents
arsenic trioxide s.k.1 mgml
k.s.kim international (sk- pharma) ltd., israel - arsenic trioxide - concentrate for solution for infusion - arsenic trioxide 1 mg / 1 ml - arsenic trioxide - arsenic trioxide s.k. is indicated for induction of remission, and consolidation in adult patients with: •newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (apl) (white blood cell count, ≤ 10x1000µl incombination with all-trans-retinoic acid (atra) •relapsed/refractory acute promyelocytic leukaemia (apl)(previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor-alpha (pml/rar-alpha) gene.the response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.
arsenic trioxide accord arsenic trioxide 10 mg/10 ml injection vial
accord healthcare pty ltd - arsenic trioxide, quantity: 10 mg - injection, concentrated - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide - for the induction of remission and consolidation in patients with acute promyelocytic leukaemia (apl) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose apl is characterised by the presence of the t(15:17) translocation or pml/rar-alpha gene expression.,for the induction of remission and consolidation in patients with previously untreated acute promyelocytic leukaemia (apl) in combination with all-trans retinoic acid (atra) and/or chemotherapy and whose apl is characterised by the presence of the t(15:17) translocation or pml/rar-alpha gene expression.
guna-pms- arsenic trioxide - estradiol - goldenseal - lachesis muta venom - magnesium phosphate - matricaria recutita - melatoni
guna spa - arsenic trioxide (unii: s7v92p67ho) (arsenic cation (3+) - unii:c96613f5av), estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e), goldenseal (unii: zw3z11d0jv) (goldenseal - unii:zw3z11d0jv), lachesis muta venom (unii: vsw71ss07i) (lachesis muta venom - unii:vsw71ss07i), magnesium phosphate, tribasic, pentahydrate (unii: 453cof7817) (magnesium cation - unii:t6v3lhy838), matricaria recutita (unii: g0r4ubi2zz) (matricaria recutita - unii:g0r4ubi2zz), melatonin (unii: jl5dk93rcl) (melatonin - uni - arsenic trioxide 6 [hp_c] in 30 ml - arsenicum album 6c mood support beta-estradiol 6x vaginal dryness chamomilla 6c calming hydrastis canadensis 6c analgesic hypophysis 8x hormonal regulation lachesis mutus 4c anxiety magnesia phosphorica 6c metabolic support melatonin 4c hormonal balance nux vomica 6c mood support oophorinum 8x irregular menses progesterone 6x irregular menses sulfur 6c detoxification temporary relief of symptoms due to premenstrual syndrome such as: - moodiness - cramping - backache take 15 minutes before meals
arsenicum- arsenicum album tablet
standard homeopathic company - arsenic trioxide (unii: s7v92p67ho) (arsenic cation (3+) - unii:c96613f5av) - arsenic trioxide 30 [hp_x] in 1 g - burning nasal discharge or diarrhea